GlassScriptPhysician profile
Theodore W Shively
NPI 1780666461
$4,489.78
in general payments reported to CMS, 2019-2025
31 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $78.37 · 2021: $249 · 2022: $328 · 2023: $1,135 · 2024: $1,255 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,573.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,392.18 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $712.34 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $483.40 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $317.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $169.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Exact Sciences Corporation | $159.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $114.32 | 2024-2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $109.36 | 2019-2025 | Austedo Xr, Austedo Xr |
| Dexcom, INC. | $103.68 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $91.97 | 2020-2024 | |
| Amgen INC. | $78.36 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $71.75 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Medtronic, INC. | $67.30 | 2022 | |
| Boston Scientific Corporation | $60.59 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $57.11 | 2021-2025 | Strensiq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $54.97 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $54.05 | 2024-2025 | |
| Qol Medical, LLC | $51.80 | 2023 | Sucraid |
| Cranial Technologies, INC | $47.69 | 2023-2024 | Doc Band |
| Eisai INC. | $46.61 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $45.55 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $32.09 | 2024-2025 | Uptravi, Opsumit |
| Avadel Cns Pharmaceuticals, LLC | $26.50 | 2025 | Lumryz |
| Hologic Sales and Service, LLC | $24.58 | 2024 | Aptima, Thinprep 2000 Processor |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.31 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $19.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.10 | 2024 | Ofev |
| Electromed, INC. | $17.89 | 2025 | Smartvest |
| Abbott Laboratories | $13.99 | 2021 | |
| Horizon Therapeutics Plc | $13.74 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $11.88 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Shively listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.